Neuragenix takes 26.1% stake in Testavec
Published
Neuragenix Ltd entered Testavec, a gene therapy testing platform, with 32,992 ordinary shares, giving it a 26.1% stake.
The filing also records Brunel University Enterprises Ltd reducing its ordinary holding; the recipient of the transferred shares is not named.
The filing was made on 4 August 2026 and covers the period from 19 July 2025 to 19 July 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | NEURAGENIX LTD | 32,992 | — | ORDINARY 32,992 |
| Decreased | BRUNEL UNIVERSITY ENTERPRISES LTD | 16,499 | -42% | ORDINARY 16,499 |
Current shareholders (2)
| Shareholder | Total shares | Share classes |
|---|---|---|
| NEURAGENIX LTD | 32,992 | ORDINARY 32,992 |
| BRUNEL UNIVERSITY ENTERPRISES LTD | 16,499 | ORDINARY 16,499 |
Contact the editorial team at editorial@fundingspotter.com